Allogene releases Phase 1 data across CAR T programs; initiates Phase 2 ALPHA2 trial

Allogene Therapeutics, Inc.

Single Dose FCA90 in LBCL achieved 67% ORR, 58% CR; 50% in CR at 6 and 12 months. No Grade 3+ CRS or neurotoxicity.
ALLO-715 in MM expansion (FCA60): 67% ORR, 42% VGPR+ (all MRD-negative), median DOR 9.2 months, longest 24 months.
ALLO-316 in RCC CD70+ patients (n=9): 100% disease control, 33% partial responses; generally manageable safety.
Phase 2 ALPHA2 trial enrolling ~100 LBCL patients; planning pivotal Phase 2 for ALLO-715 and evaluating ALLO-316 expansion.
Research update: Dagger technology aims to delay AlloCAR T rejection; ALLO-605 trial paused for manufacturing review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.